Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Oramed Pharmaceuticals Inc.
JERUSALEM, February 18, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that Dr. Ehud Arbit, Oramed's Director of Research & Development, will be presenting at the 4th Annual Drug Delivery and Formulation Summit in Berlin, Germany. The presentation, titled "Formulating Protein Therapies for Oral Delivery and Understanding Implications on Treatment and Patient Compliance: An Industry Case Study," will be given on Tuesday, February 19th, at the biologics session from 9:55-10:35am. The summit venue is the Maritim Pro Arte Hotel.
The Drug Delivery & Formulation Summit sources and presents leading global case studies from such top-tier pharmaceutical companies as Pfizer, GSK, Novartis, Merck and Eli Lilly. The Summit provides a forum for pharmaceutical industry experts to present, discuss and debate scientific and strategic advancements in pharmaceutical development.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit http://www.oramed.com.
The company's fact sheet,the content of which is not part of this press release, can be viewed here.
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
By: Jenn Schanz firstname.lastname@example.org Keven Skiles has been biking since he can remember. He rides everywhere, sometimes biking the same path three or four times a day. While riding his usual route onMore >>
While riding his usual route on the bike path in front of McDonalds on 56th and Old Cheney road, Keven was clipped by a car that he says, wasn't paying attention after he pulled out too far at a stop sign.More >>
By: Kayla Bremer email@example.com With Memorial weekend just around the corner, gas prices are expected to rise even more. Just 4 cents separate the current cost and Lincoln's all time high, and peopleMore >>
With Memorial weekend just around the corner, gas prices are expected to rise even more.More >>
By: KLKN Newsroom firstname.lastname@example.org The City of Lincoln will swear in three new City Council members at Monday's meeting. Roy Christensen, Trent Fellers and Leirion Gaylor Baird will be sworn in. They'llMore >>
The City of Lincoln will swear in three new City Council members at Monday's meeting.More >>
By: KLKN Newsroom email@example.com Two people are in custody after Jefferson County Deputies find meth in their car. Deputies said it happened on Friday around 3 p.m. in Reynolds. After they cited theMore >>
Two people are in custody after Jefferson County Deputies find meth in their car.More >>
By: KLKN Newsroom firstname.lastname@example.org After nearly 40 years with the Human Resources Department, Nancy Biggs and Sue Wright are retiring from LPS. To celebrate their careers and years of service, a specialMore >>
After nearly 40 years with the Human Resources Department, Nancy Biggs and Sue Wright are retiring from LPS.More >>
By: Jenn Schanz email@example.com "Student loans, any kind of debt, make sure my family is taken care of, and travel." That's what Madeline Hendrix would do if she won the 600 million dollar PowerballMore >>
For the superstitious Powerball jackpot player, number choice, time of day, and even where a ticket is bought are huge factors. More >>
By: Kayla Bremer firstname.lastname@example.org Fallbrook Town Center in north Lincoln was crowded with people and full of activities all centered around the dogs. It's for one of the Capital Humane Society'sMore >>
Fallbrook Town Center in north Lincoln was crowded with people and full of activities all centered around the dogs. More >>
By: KLKN Newsroom email@example.com LINCOLN, Neb. (AP) Authorities say Nebraska's preliminary unemployment rate declined to 3.7 percent in April after registering 3.8 percent for four straight months. TheMore >>
Authorities say Nebraska's preliminary unemployment rate declined to 3.7 percent in April after registering 3.8 percent for four straight months.More >>